Squamous cell carcinoma - Қабыршақ Тәрізді Жасушалы Карцинома
☆ Германияның 2022 жылғы Stiftung Warentest нәтижелерінде тұтынушылардың ModelDerm-ке қанағаттануы ақылы телемедициналық кеңестерге қарағанда сәл ғана төмен болды.
Squamous cell carcinoma well differentiated ― Көршілес актиникалық кератоз байқалады.
References
Squamous cell carcinoma (SCC) Америка Құрама Штаттарындағы тері қатерлі ісігі basal cell carcinoma кейін екінші орында. Ол әдетте actinic keratosis деп аталатын ісік алды зақымданудан басталып, дененің басқа бөліктеріне таралуы мүмкін. Негізгі себеп - күннің ультракүлгін (УК) сәулеленуінің әсері, ол уақыт өте келе жинақталады. Емдеу әдетте хирургиялық алып тастауды қамтиды, әсіресе бас пен мойындағы СКҚ үшін. Сәулелік терапия - бұл егде жастағы науқастарға немесе операция жасай алмайтындарға. Иммуносупрессия СКҚ қаупін арттырады. Сирек болса да, SCC таралуы мүмкін, әсіресе иммундық жүйесі әлсіреген науқастарда. СКҚ бар адамдар үшін тұрақты тексеру және күннен қорғану маңызды.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) адамдар арасында жиі кездесетін екінші қатерлі ісік болып табылады және оның саны артып келеді. CSCC әдетте жақсы клиникалық мінез-құлықты көрсетсе де, ол жергілікті жерде де, дененің басқа бөліктеріне де таралуы мүмкін. Ғалымдар жаңа емдеуге әкелетін CSCC дамуына қатысатын нақты жолдарды анықтады. Мутациялардың көп болуы және иммунитеті төмендеген пациенттердегі тәуекелдің жоғарылауы иммунотерапияның дамуына түрткі болды. Бұл шолуда CSCC генетикалық тамырлары мен нақты молекулалар мен иммундық жүйеге бағытталған соңғы емдеу әдістері қарастырылады.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Диагностика мен емдеу
#Dermoscopy
#Skin biopsy